R 1454
Alternative Names: R-1454Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Roche
- Class Antineoplastics
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer in USA
- 31 Dec 2004 Phase-I clinical trials in Non-small cell lung cancer in USA (unspecified route)